Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.

@article{Marberger2006DrugI5,
  title={Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.},
  author={Michael J Marberger},
  journal={Nature clinical practice. Urology},
  year={2006},
  volume={3 9},
  pages={495-503}
}
Benign prostatic hyperplasia (BPH) is a common problem among older men, which is characterized by an enlarged prostate, lower urinary tract symptoms, and decreased flow of urine. It is a progressive disease that can lead to complications such as acute urinary retention (AUR) or a need for BPH-related surgery in some men. Dihydrotestosterone is the primary androgen involved in both normal and abnormal prostate growth and 5alpha-reductase inhibitors (5ARIs) inhibit the conversion of testosterone… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Androgens and prostate disease

Asian journal of andrology • 2014
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…